James Stice
About James Stice
James Stice is an Associate Director at BridgeBio, where he focuses on innovative therapeutic approaches for cancer treatment. He holds a Ph.D. in Molecular, Cellular, and Integrative Physiology and has extensive experience in cancer research and drug development.
Current Role at BridgeBio
James Stice currently serves as Associate Director at BridgeBio, a position he has held since 2023. His role is based in South San Francisco, California, and operates in a hybrid work environment. In this capacity, he continues to contribute to the development of innovative therapeutic solutions.
Previous Experience at BridgeBio
Prior to his current role, James Stice worked at BridgeBio as Principal Scientist from 2021 to 2023. During this time, he led significant projects, including an academic-industry partnership that developed a new treatment approach for castration-resistant prostate cancer (CRPC), which is now advancing to clinical trials. He also served as a Senior Scientist at BridgeBio for seven months in 2020.
Education and Expertise
James Stice earned his Doctor of Philosophy (Ph.D.) in Molecular, Cellular, and Integrative Physiology from the University of California, Davis, where he studied from 2004 to 2009. He also holds a Bachelor of Science degree with a double major in Biological Sciences and Psychology from the same institution, completed from 1998 to 2003. His expertise includes significant experience with animal models, particularly in the study of breast and prostate tumor growth and metastasis.
Career Background
James Stice has a diverse career in the biotechnology and pharmaceutical sectors. He worked as a Postdoctoral Scholar at Duke University from 2009 to 2016. He then joined ORIC Pharmaceuticals as a Scientist from 2016 to 2018, followed by a role as Senior Scientist at UNITY Biotechnology from 2018 to 2020. Earlier in his career, he gained experience as an intern at Genentech from 2007 to 2008.
Research Contributions
Throughout his career, James Stice has developed innovative, mechanism-based screening methods utilizing combinatorial peptide and protein phage display technologies aimed at small molecule therapeutics. His research has focused on advancing understanding and treatment options for cancer, particularly prostate cancer.